AR069206A1 - Derivados de 2-pirazinona, proceso para preparalos, composiciones farmaceuticas que los comprenden, proceso de preparacion de las mismas y usos en el tratamiento de trastornos osteoarticularesy del aparato respiratorio, entre otros. - Google Patents

Derivados de 2-pirazinona, proceso para preparalos, composiciones farmaceuticas que los comprenden, proceso de preparacion de las mismas y usos en el tratamiento de trastornos osteoarticularesy del aparato respiratorio, entre otros.

Info

Publication number
AR069206A1
AR069206A1 ARP080104851A ARP080104851A AR069206A1 AR 069206 A1 AR069206 A1 AR 069206A1 AR P080104851 A ARP080104851 A AR P080104851A AR P080104851 A ARP080104851 A AR P080104851A AR 069206 A1 AR069206 A1 AR 069206A1
Authority
AR
Argentina
Prior art keywords
methyl
dihydropyrazine
oxo
carboxamide
cyanophenyl
Prior art date
Application number
ARP080104851A
Other languages
English (en)
Inventor
Debra Ainge
David Chapman
Martin Lindsjo
Hans Lonn
Af Rosenschoeld Magnus Munck
Antonios Nikitidis
Michael Lundkvist
John Pavey
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40626002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR069206(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR069206A1 publication Critical patent/AR069206A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Reivindicacion 1: Un compuesto caracterizado porque se selecciona de: 6-[1-(4-cianofenil)-1H-pirazol-5-il]-5-metil-3-oxo-4-[3-(trifluorometil)fenil]-3,4-dihidropirazina-2-carboxamida; 6-[1-(4-clorofenil)-1H-pirazol-5-il]-5-metil-3-oxo-4-[3-(trifluorometil)fenil]-3,4-dihidropirazina-2-carboxamida; 6-[1-(5-cloropiridin-2-il)-1H-pirazol-5-il]-5-metil-3-oxo-4-[3-(trifluorometil)fenil]-3,4-dihidropirazina-2-carboxamida; 6-[1-(4-cianofenil)-3-metil-1H-pirazol-5-il]-5-metil-3-oxo-4-[3-(trifluorometil)fenil]-3,4-dihidropirazina-2-carboxamida; 4-(3-cianofenil)-6-[1-(4-cianofenil)-1H-pirazol-5-il]-N-ciclopropil-5-metil-3-oxo-3,4-dihidropirazina-2-carboxamida; y 6-(1-(4-cianofenil)-4,4-dimetil-4,5-dihidro-1H-imidazol-2-il)-5-metil-3-oxo-4-(3-(trifluorometil)fenil)-3,4-dihidropirazina-2-carboxamida; o una sal farmacéuticamente aceptable de uno cualquiera de los mismos. Reivindicacion 2: Un compuesto de acuerdo con la reivindicacion 1, caracterizado porque es 6-[1-(4-cianofenil)-1H-pirazol-5-il)-5-metil-3-oxo-4-[3-(trifluorometil)fenil]-3,4-dihidropirazina-2-carboxamida o una sal farmacéuticamente aceptable del mismo. Reivindicacion 3: Un compuesto de acuerdo con la reivindicacion 2, caracterizado porque es 6-[1-(4-cianofenil)-1H-pirazol-5-il)-5-metil-3-oxo-4-[3-(trifluorometil)fenil]-3,4-dihidropirazina-2-carboxamida Forma A.
ARP080104851A 2007-11-06 2008-11-05 Derivados de 2-pirazinona, proceso para preparalos, composiciones farmaceuticas que los comprenden, proceso de preparacion de las mismas y usos en el tratamiento de trastornos osteoarticularesy del aparato respiratorio, entre otros. AR069206A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98571307P 2007-11-06 2007-11-06

Publications (1)

Publication Number Publication Date
AR069206A1 true AR069206A1 (es) 2010-01-06

Family

ID=40626002

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104851A AR069206A1 (es) 2007-11-06 2008-11-05 Derivados de 2-pirazinona, proceso para preparalos, composiciones farmaceuticas que los comprenden, proceso de preparacion de las mismas y usos en el tratamiento de trastornos osteoarticularesy del aparato respiratorio, entre otros.

Country Status (23)

Country Link
US (1) US8466284B2 (es)
EP (1) EP2217591A4 (es)
JP (1) JP2011502982A (es)
KR (1) KR20100096131A (es)
CN (1) CN101918391B (es)
AR (1) AR069206A1 (es)
AU (1) AU2008325288B2 (es)
BR (1) BRPI0819258A2 (es)
CA (1) CA2703996A1 (es)
CL (1) CL2008003301A1 (es)
CO (1) CO6270241A2 (es)
CR (1) CR11416A (es)
DO (1) DOP2010000134A (es)
EA (1) EA017297B1 (es)
IL (1) IL205209A0 (es)
MX (1) MX2010004673A (es)
NI (1) NI201000079A (es)
PE (1) PE20091565A1 (es)
SV (1) SV2010003559A (es)
TW (1) TW200924770A (es)
UY (1) UY31456A1 (es)
WO (1) WO2009061271A1 (es)
ZA (1) ZA201002853B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111225921A (zh) * 2017-10-24 2020-06-02 拜耳股份公司 被取代的三唑衍生物的前药及其用途

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
PE20091565A1 (es) 2007-11-06 2009-11-06 Astrazeneca Ab Derivados de 2-pirazinona como inhibidores de la elastasa de los neutrofilos
TW201036957A (en) * 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
KR20120099639A (ko) * 2009-10-02 2012-09-11 아스트라제네카 아베 호중구 엘라스타제의 억제제로서 사용되는 2-피리돈 화합물
WO2011110852A1 (en) 2010-03-10 2011-09-15 Astrazeneca Ab Polymorphic forms of 6- [2- (4 -cyanophenyl) - 2h - pyrazol - 3 - yl] - 5 -methyl - 3 - oxo - 4 - (trifluoromethyl - phenyl) 3,4-dihydropyrazine-2-carboxylic acid ethylamide
DE102010030187A1 (de) 2010-06-16 2011-12-22 Bayer Schering Pharma Aktiengesellschaft 4-Cyan-2-sulfonylphenyl)pyrazolyl-substituierte Pyridinone und Pyrazinone und ihre Verwendung
TW201247631A (en) 2011-04-28 2012-12-01 Du Pont Herbicidal pyrazinones
EP2872509B1 (en) 2012-07-12 2016-09-14 Chiesi Farmaceutici S.p.A. Inhibition of enzymes
US9102624B2 (en) 2012-08-23 2015-08-11 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057920A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057926A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US10099203B2 (en) 2015-02-23 2018-10-16 The Royal Institution For The Advancement Of Learning/Mcgill University Method for the preparation of metal-organic compounds
CN104788355A (zh) * 2015-04-02 2015-07-22 聊城大学 一种含氮杂环苯腈或邻苯二腈化合物的合成方法
US20220354833A1 (en) 2019-09-17 2022-11-10 Mereo Biopharma 4 Limited Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease
WO2021209739A1 (en) 2020-04-16 2021-10-21 Mereo Biopharma 4 Limited Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
TW202325294A (zh) 2021-10-20 2023-07-01 英商梅瑞奧生物製藥４有限公司 用於治療纖維化之嗜中性球彈性蛋白酶抑制劑
CN117398373A (zh) * 2022-07-07 2024-01-16 上海汇伦医药股份有限公司 西维来司他的新用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2358891A1 (fr) 1976-07-22 1978-02-17 Yamanouchi Pharma Co Ltd Composes heterocycliques contenant un azote, utilise comme agents analgesiques et anti-inflammatoires
DE2706977A1 (de) 1977-02-18 1978-08-24 Hoechst Ag Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung
EP0008864A1 (en) 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
JPH02152966A (ja) 1988-12-05 1990-06-12 Otsuka Pharmaceut Co Ltd ４−ヒドロキシカルボスチリル誘導体
US5521179A (en) 1991-04-18 1996-05-28 Zeneca Limited Heterocyclic amides
US5441960A (en) 1992-04-16 1995-08-15 Zeneca Limited 1-pyrimidinylacetamide human leukocyte elastate inhibitors
CZ9902016A3 (cs) 1996-12-05 1999-11-17 Amgen Inc. Substituované pyrimidinonové a pyridonové sloučeniny a způsoby jejich použití
JPH1171351A (ja) 1997-08-29 1999-03-16 Ss Pharmaceut Co Ltd 置換キノロン誘導体及びこれを含有する医薬
HU1300187D0 (hu) 2000-06-12 2004-03-01 Eisai R&D Man Co Ltd 1,2-Dihidropiridin-származékok, eljárás elõállításukra és alkalmazásuk
WO2002053543A1 (fr) 2000-12-28 2002-07-11 Shionogi & Co., Ltd. Derive de pyridone ayant une affinite pour le recepteur cannabinoide de type 2
CA2456292A1 (en) 2001-08-14 2003-02-27 Toyama Chemical Co., Ltd. Novel virus growth inhibitor and/or virucidal method, and novel pyrazine nucleotide or pirazine nucleoside analog
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
GB2383326A (en) 2001-12-20 2003-06-25 Bayer Ag Antiinflammatory dihydropyridines
MXPA03000145A (es) 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
EP1477186B1 (en) 2002-02-19 2009-11-11 Shionogi & Co., Ltd. Antipruritics
CA2496815C (en) 2002-08-27 2011-04-26 Bayer Healthcare Ag Dihydropyridinone derivatives
GB2392910A (en) 2002-09-10 2004-03-17 Bayer Ag 2-Oxopyrimidine derivatives and their use as human leukocyte elastase inhibitors
TW200500341A (en) 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
NZ540791A (en) 2003-02-13 2009-09-25 Banyu Pharma Co Ltd Novel 2-pyridinecarboxamide derivatives
SE0302324D0 (sv) 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302323D0 (sv) 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
EP1720857B1 (en) 2004-02-19 2011-07-13 Bayer Schering Pharma Aktiengesellschaft Dihydropyridinone derivatives
CA2557271C (en) 2004-02-26 2012-08-21 Bayer Healthcare Ag 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
TWI360539B (en) 2004-10-28 2012-03-21 Shionogi & Co 3-carbamoyl-2-pyridone derivatives
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
TW200700392A (en) 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
GB0512940D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Compounds and their use
GB0605469D0 (en) 2006-03-17 2006-04-26 Argenta Discovery Ltd Multimers of heterocyclic compounds and their use
EA018061B1 (ru) 2006-05-04 2013-05-30 Пульмаджен Терапьютикс (Инфлэмэйшн) Лимитед Тетрагидропирролопиримидиндионы и их применение в качестве ингибиторов эластазы нейтрофилов человека
TW200808771A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
RU2485115C2 (ru) 2006-07-14 2013-06-20 Новартис Аг Производные пиримидина в качестве ингибиторов alk-5
WO2008030158A1 (en) 2006-09-04 2008-03-13 Astrazeneca Ab Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors
WO2008104752A1 (en) 2007-02-26 2008-09-04 Astrazeneca Ab Dihydropyridones as elastase inhibitors
WO2009058076A1 (en) 2007-11-02 2009-05-07 Astrazeneca Ab 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
PE20091565A1 (es) 2007-11-06 2009-11-06 Astrazeneca Ab Derivados de 2-pirazinona como inhibidores de la elastasa de los neutrofilos
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111225921A (zh) * 2017-10-24 2020-06-02 拜耳股份公司 被取代的三唑衍生物的前药及其用途

Also Published As

Publication number Publication date
AU2008325288B2 (en) 2011-12-22
KR20100096131A (ko) 2010-09-01
NI201000079A (es) 2011-03-24
EP2217591A4 (en) 2011-10-26
CN101918391B (zh) 2013-06-05
CN101918391A (zh) 2010-12-15
CO6270241A2 (es) 2011-04-20
JP2011502982A (ja) 2011-01-27
SV2010003559A (es) 2010-09-13
EA017297B1 (ru) 2012-11-30
WO2009061271A1 (en) 2009-05-14
ZA201002853B (en) 2011-10-26
BRPI0819258A2 (pt) 2017-05-02
UY31456A1 (es) 2009-07-17
CA2703996A1 (en) 2009-05-14
CL2008003301A1 (es) 2009-10-16
IL205209A0 (en) 2010-12-30
US8466284B2 (en) 2013-06-18
AU2008325288A1 (en) 2009-05-14
MX2010004673A (es) 2010-05-27
US20100280048A1 (en) 2010-11-04
EP2217591A1 (en) 2010-08-18
EA201000702A1 (ru) 2010-12-30
DOP2010000134A (es) 2010-10-15
PE20091565A1 (es) 2009-11-06
CR11416A (es) 2010-08-27
TW200924770A (en) 2009-06-16

Similar Documents

Publication Publication Date Title
AR069206A1 (es) Derivados de 2-pirazinona, proceso para preparalos, composiciones farmaceuticas que los comprenden, proceso de preparacion de las mismas y usos en el tratamiento de trastornos osteoarticularesy del aparato respiratorio, entre otros.
AR112118A2 (es) Inhibidores de pi-3 quinasa
AR122776A2 (es) Composiciones parasiticidas que comprenden un agente activo de isoxazolina, sus métodos y usos
PH12013500773A1 (en) Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
PH12017502425A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
CL2010001608A1 (es) Compuestos derivados de 2-(3-(5-oxo-4,5-dihidro-pirazin-2-il)-fenil)-4,5-dihidro-2h-isoquinolin-1-ona y 2-(3-(5-oxo-4,5-dihidro-pirazin-2-il)-fenil)-3,4-dihidro-2h-isoquinolin-1-ona, inhibidores de quinasa; composicion farmaceutica; utiles en el tratamiento de estados patologicos inflamatorios y/o inmunes.
PE20170695A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
AR058901A1 (es) Compuestos derivados de hidantoina, utiles para el tratamiento de trastornos inflamatorios y composicion farmaceutica que los comprende
PE20120626A1 (es) Composiciones farmaceuticas que comprende nilotinib
AR076692A1 (es) Piperidinas sustituidas
AR067540A1 (es) Compuesto de aril (isoxazol-4-il-metoxilo) , su uso para preparar un medicamento y composicion farmaceutica que lo comprende
PE20160223A1 (es) Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1
BR112015021549A2 (pt) inibidores de piridina cinase cdk9
PE20070795A1 (es) Compuestos pirazol-urea-heterociclicos como inhibidores de cinasa
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
MX2007010105A (es) Derivados de 4-oxoquinazolin-3-ilbenzamida para el tratamiento de enfermedades mediadas por citocinas.
ECSP109889A (es) Composiciones terapeuticas y usos de las mismas
UY29766A1 (es) Formas cristalinas delta y épsilon de mesilato de imatinib
AR074426A1 (es) Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende
PE20090895A1 (es) Derivados de triazol como inhibidores de la jak quinasa
EA201892415A1 (ru) Полиморфная форма n-{6-(2-гидроксипропан-2-ил)-2-[2-(метилсульфонил)этил]-2н-индазол-5-ил}-6-(трифторметил)пиридин-2-карбоксамида
CL2009000906A1 (es) Compuestos derivados de 4-imidazolil y 4-triazolil de 2-(6-(4-cicloalquilpiperazin-1-il)pirimidin-4-il)-1h-pirazol-3(2h)ona inhibidores de hif-prolil-4-hidroxilasas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de enfermedades cardiovasculares, renales y hematologicas.
UY31125A1 (es) Formas amorfas estabilizadas de mesilato de imatinib
PE20071337A1 (es) Nanoparticulas que comprenden imatinib, composiciones farmaceuticas y dispositivos que comprenden dichas nanoparticulas y uso farmaceutico de las mismas
AR073064A1 (es) 5-aminopirazoles sustituidos y uso de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure